No­var­tis hands back PD-1 in­hibitor to BeiGene af­ter reg­u­la­to­ry hur­dles

BeiGene will re­gain the full glob­al rights to its an­ti-PD-1 an­ti­body tislelizum­ab from No­var­tis af­ter the com­pa­nies ran in­to reg­u­la­to­ry hur­dles in the US, it said Tues­day morn­ing.

Min­utes lat­er, BeiGene said the Eu­ro­pean Com­mis­sion ap­proved the check­point in­hibitor, to be sold as Tevim­bra, as a monother­a­py for adults with un­re­sectable, lo­cal­ly ad­vanced or metasta­t­ic esophageal squa­mous cell car­ci­no­ma (ES­CC) af­ter pri­or plat­inum-based chemother­a­py. The FDA al­so ac­cept­ed the bi­o­log­ics li­cense ap­pli­ca­tion for the first-line ad­vanced ES­CC treat­ment can­di­date, and will make a de­ci­sion in the sec­ond half of next year, BeiGene said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER